Dexcom’s 15-day CGM Adds Wear Time, Accuracy to Current G7

TOPLINE:

The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration, it is more accurate than the current 10-day G7.

METHODOLOGY:

• The prospective, multicenter study of the 15-day G7 sensor was conducted in 130 adults with diabetes (113 type 1, 17 type 2) using intensive insulin therapy, at six clinical US sites.
• In-clinic visits occurred on days 1-3, 4-7, 9-12, and 13-15.5, during which G7 glucose readings were compared with venous blood analyzed with the yellow springs instrument (YSI) 2300 Stat Plus glucose analyzer.
• A total of 20,310 matched pairs of readings were used for accuracy analyses.

TAKEAWAY:

• The overall mean absolute relative difference (MARD) for the 15-day G7 CGM system was 8.0%.
• The overall proportion of sensors with > 80% of readings within X% of YSI values ≥ 70 mg/dL or within X mg/dL of YSI < 70mg/dL was 87.7%, 94.2%, 98.9%, and 99.8% for 15%/15 mg/dL, 20%/20 mg/dL, 30%/30 mg/dL, and 40%/40 mg/dL, respectively. Accuracy was maintained across the four wear periods and across patient demographic subgroups.
• Of 5019 alerts arising when the hypoglycemia alert threshold was set to 70 mg/dL, 82.0% were true alerts, as corroborated by the YSI within 15 minutes.
• There were no serious adverse events.

IN PRACTICE:

“A MARD of 8% improves upon the accuracy of currently-available G7, of 8.2%. [The 15-day G7] demonstrated high accuracy across wear periods, glucose concentrations and rate of glucose change. Extended sensor wear with a fast warmup of 27 minutes is the lowest that’s available in the marketplace. It’s likely that with all these features, it might facilitate patients’ behavior and thus improve glucose management in people with diabetes.”

SOURCE:

This study was conducted by Satish Garg, MD, Professor of Medicine and Pediatrics at the Barbara Davis Center for Diabetes, University of Colorado, and colleagues. Garg presented the results on March 20, 2025 at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025 meeting and they were simultaneously published in Diabetes Technology and Therapeutics.

LIMITATIONS:

The study population was an all-adult population. Patients were with type 1 and type 2 diabetes using intensive insulin therapy.

DISCLOSURES:

This study was funded by Dexcom. Garg had served on advisory boards and received consulting fees from Medtronic, Eli Lilly, Abbott Diabetes Care, and Novo Nordisk. Through the University of Colorado, he had received research grants from Eli Lilly, Medtronic, Dario, Diasome, Lexicon, and Dexcom.